Stockreport

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development [Yahoo! Finance]

MaxCyte, Inc.  (MXCT) 
PDF portfolio across a variety of cell types including T cells, Gamma-Delta T cells and NK Cells. ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc , (Nasdaq: [Read more]